Document is current

Article History

Received: 6 June 2024

Accepted: 4 July 2024

First Online: 19 July 2024

Declarations

:

: At the time of publication Victor L. Perez was affiliated with the Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA. At the time of the study Victor L. Perez was affiliated with the Department of Ophthalmology, Duke Eye Center, Duke University School of Medicine, Durham, NC, USA and Foster Center for Ocular Immunology, Duke Eye Institute, Durham, NC, USA. Marta Villalba: None; Victor Sabates: None; Sarp Orgul: None; Victor L. Perez: Alcon, Dompe, Kiora Pharmaceutical, Kala, Novartis, Trefoil, Quidel, National Institutes of Health/National Eye Institute: R01EY030283, R01EY024485, Duke NIH Center Core Grant and Duke Research to Prevent Blindness Unrestricted Grant; Swarup S. Swaminathan: Sight Sciences, Ivantis, Heidelberg Engineering, Lumata Health, Abbvie, Topcon, National Institutes of Health/National Eye Institute (K23-EY033831); Alfonso L. Sabater: Brill Pharma, Ocubio, Tissuecor, Abbvie, GlaxoSmithKline.

: This study was approved by the Institutional Review Board of the University of Miami Miller School of Medicine. The protocol conformed to the requirements of the US Health Insurance Portability and Accountability Act and the tenets of the Declaration of Helsinki. Patients in the study were evaluated at the Bascom Palmer Eye Institute and informed consent was obtained from all of them prior to clinical examination.

: The Corneal Esthesiometer Brill is classified as a Class IIa medical device in Europe and approved with the CE mark. In the USA, the device has been registered as a Class I medical device, 510K exempt, and the US Food and Drug Administration has granted permission to market it. The device complies with the regulatory requirements of both territories.